What the FDA labels say about taking them together
Clarithromycin and everolimus
Everolimus's FDA label (Zortress) of February 12, 2026 names clarithromycin in its drug interactions section; the clarithromycin label PlainMeds reads does not name everolimus. The everolimus label: “Concurrent treatment with strong inhibitors and inducers of CYP3A4 is not recommended.”
Check it at the source: the clarithromycin FDA label on DailyMed (effective April 9, 2026, Solaris Pharma Corporation); the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation).
What does the clarithromycin label say about everolimus?
Clarithromycin's label (effective April 9, 2026) does not name everolimus in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Clarithromycin), Solaris Pharma Corporation, effective April 9, 2026 (SPL set 4d42821d-ce7a-7d64-e063-6294a90a0875), via openFDA; the full label on DailyMed
What does the everolimus label say about clarithromycin?
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), drug interactionsConcurrent treatment with strong inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, boceprevir, telaprevir) and inducers (e.g., rifampin, rifabutin) of CYP3A4 is not recommended.
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), warnings and precautionsInhibitors and Inducers of CYP3A4 Coadministration of Zortress with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, boceprevir, telaprevir) or strong CYP3A4 inducers (e.g., rifampin, rifabutin) is not recommended without close monitoring of everolimus whole blood trough concentrations [see Drug Interactions (7)].
Source: FDA drug label (Zortress, NDA021560), Novartis Pharmaceuticals Corporation, effective February 12, 2026 (SPL set e082a024-7850-400b-a5c2-2a140612562a), via openFDA
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clarithromycin | Everolimus | |
|---|---|---|
| Labeled for | Bacterial infections, Acid reflux and ulcers | Breast cancer, Seizures and epilepsy, Organ transplant rejection |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.466 per tablet 500 mg tablet | $26.32 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once